Katy Beckermann, MD, PhD – Vanderbilt UniversityThe phase 3 TiNivo-2 study (NCT04987203), sponsored by AVEO Pharmaceuticals, Inc., recently evaluated tivozanib…
Browsing: Kidney
On September 12, 2024, the U.S. Food and Drug Administration (FDA) approved Tecentriq Hybreza, the first subcutaneous (SC) formulation of…
AVEO Oncology, a subsidiary of LG Chem, has announced the acceptance of its Phase 3 TiNivo-2 trial for a Proffered…
Author: Dr. Regina Barragan-Carillo, City of HopeOverview: At ASCO 2024, Dr. Regina Barragan-Carillo from City of Hope Cancer Center shared…
…Dr. Sumanta (Monty) Kumar Pal, M.D., FASCO highlights some of the top data and presentations being presented in kidney and bladder…
AVEO Oncology Fotivda Video Pre-Roll
Presented By: Dalia Kaakour, MD – University of California, Irvine Date: Aug 12, 2023 In the realm of oncology and…
Pembrolizumab plus Lenvatinib, individually known for their robust anti-cancer mechanisms, when combined, show significant promise in treating advanced renal cell…
FOTIVDA is Aveo’s marketed product for treating advanced renal cell carcinoma, primarily used as a later line agent in the…
Corina Dutcus, MD from Eisai Inc provided a summary of the findings from a clinical trial evaluating the combination of…
CD70: How Does ALLO-316 Eliminate or Destroy Malignancies in the TRAVERSE Trial? Samer Srour, MB ChB, MS By Samer Srour,…
Renal Cell Carcinoma Trials: Guidelines and Eligibility According to ASCO-FCR: An Overview of RCC Trials Anna Odell by Anna Odell,…
Renal Cell Carcinoma Trials: ASCO-FCR Guidelines for Renal Cell Carcinoma Trial Eligibility Ishann Sehgal by Ishann Sehgal, City of Hope…
Belzutifan and other Novel Therapies in Genitourinary Oncology 2023 By Rana McKay, MD – University of California San Diego We’re…
CHECKMATE-914 Phase 3 Dr. Brian Rini, MD [2022] CHECKMATE-914 Trial The purpose of this study is to determine if the…
COSMIC-313 Phase 3 Kidney Cancer Trial [2022] COSMIC-313 Kidney Cancer Trial I’m going to talk today about COSMIC-313 ( Ipi/Nivo…
CHECKMATE-914 Phase 3 Kidney Cancer Trial [2022] CHECKMATE-914 Trial I’m going to talk to you today about CHECKMATE-914 clinical trial,…
Enfortumab Vedotin was tested in a randomized phase 3 trial in patients with metastatic urothelial cancer who had previously received…
Richard Woodman, MD Chief Clinical Officer, Oncology Business Group at Eisai, Inc.. In this video, he speaks about the ASCO…
Richard Woodman, MD Chief Clinical Officer, Oncology Business Group at Eisai, Inc.. In this video, he speaks about the ASCO…
Toni Choueiri, MD, Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Jerome and Nancy Kohlberg Chair…
Toni Choueiri, MD, Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Jerome and Nancy Kohlberg Chair…
Laurence Albiges, M.D., Ph.D., Vice-Chair Medical Oncology Department at Gustave Roussy. In this video, she speaks about the ASCO GU…
Laurence Albiges, M.D., Ph.D., Vice-Chair Medical Oncology Department at Gustave Roussy. In this video, she speaks about the ASCO GU…
Dharmesh Gopalakrishnan, MD, a Hematology-Oncology Fellow at Roswell Park speaks about the ASCO 2021 Abstract – Immune checkpoint inhibitors (ICI)…
Brian Rini, MD, Professor of Medicine from Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center speaks about Pembrolizumab (pembro) plus axitinib…
Brian Rini, MD Professor of Medicine from Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center speaks about AVEO Oncology Announces U.S.…
Xiaoqiang Wang, MD, Ph.D., MB (ASCP) from the City of Hope speaks about White button mushrooms could slow progression of…
Bradley McGregor, MD of the Dana-Farber Cancer Institute speaks about Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.Link to…
Zeynep Busra Zengin, MD, a postdoctoral fellow at the City of Hope, a comprehensive cancer center discusses the ASCO GU…
Sumanta (Monty) K. Pal, MD of the City of Hope speaks about A randomized, multi-arm comparison of targeted therapies for…
Sumanta Pal, M.D., co-director of the Kidney Cancer Program at City of Hope ESMO Virtual Congress 2020: COSMIC-021, Cabozantinib in…
Andrew Lachlan Schmidt, M.B., B.S. of Dana-Farber Cancer Institute speaks about Novel Therapeutic Approaches and the Evolution of Drug Development…
Matthew Tucker, Clinical Fellow at Vanderbilt University Medical Center discusses Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma.Quick SummaryImmunotherapy-based…
Maxime Meylan, PhD of the Centre de Recherche des Cordeliers explains the ESMO Virtual Congress 2020: Clear Cell Renal Cell…
Andrea B. Apolo, MD of NIH National Cancer Institute speaks about the ESMO 2020 abstract New First-Line Treatment Option For…
Rana R. McKay, MD UC SD Health discusses ASCO 2020 abstract entitled Optimized management of nivolumab (Nivo) and ipilimumab (Ipi)…
Ramaprasad Srinivasan, M.D., Ph.D. – NIH National Cancer Institute Results from a phase II study of bevacizumab and erlotinib in…
David A. Braun, MD, PhD from Dana Farber discusses an ASCO 2020 abstract entitled Immunogenomic characterization of advanced clear cell…
Eric Jonasch, MD @MDAndersonNews #ASCO2020 gives an overview of the Phase II study of the oral HIF-2α inhibitor MK-6482 for…
Elizabeth Plimack, MD @FoxChaseCancer gives an updated analysis of KEYNOTE-426 at ASCO 2020 Pembrolizumab plus axitinib versus sunitinib as first-line…
Tanya Dorff, MD Associate Clinical Professor of MedicineHead of Genitourinary Cancer Program City of Hope discusses Genitourinary Cancers:Evolving Practices and…
Hans Hammers, MD of UT Southwestern Medical Center discusses the role of radiation in kidney cancer at the KCA 2019.
Meredith M. Regan,1 Michael B. Atkins,2 Thomas Powles,3 Lillian Werner,4 Charlene Mantia,5 Shuo Yang,6 Jennifer L. Johansen,6 Sumati Rao,6 Kyna…
Chung-Han Lee1, Amishi Y. Shah2, Vicky Makker1, Matthew Taylor3, David Shaffer4, James J. Hsieh5, Allen L. Cohn6, Chris DiSimone7, Alvaro…
Nicholas Vogelzang, MD of Comprehensive Cancer Centers discusses his moderation of modern imaging technology.
Nicholas Vogelzang, MD of Comprehensive Cancer Centers discusses his moderation of modern imaging technology.
Ulka Vaishampayan, MD of @karmanoscancer explains her moderation of management for clinical cases in kidney cancer.
James Brugarolas, M.D., Ph.D. Director, Kidney Cancer Program Principal Investigator, Kidney Cancer SPORE Sherry Wigley Crow Endowed Chair in Cancer…
Matt Campbell MD Assistant Professor GU Medical Oncology discusses The Argument for Front Line TKI based treatment for non-clear cell…
Viraj Master MD PhD FACS Professor Fray F. Marshall Chair in Urological Research Department of Urology Director of Integrative Oncology…
Alexander Kutikov, MD, FACS Professor and Chief, Urologic Oncology Fox Chase Cancer Center, Philadelphia, PA discusses Treatment of the Cystic…
Alexander Kutikov, MD, FACS Professor and Chief, Urologic Oncology Fox Chase Cancer Center, Philadelphia, PA discusses Treatment of the Cystic…
Steven C. Campbell, MD, PhD Professor Surgery, Vice Chair, Program Director Section of Urologic Oncology, Department of Urology Glickman Urological…
Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Changing Paradigms…
Ritesh Kotecha, Erika Gedvilaite, Samuel Murray, Ashley Foster, Robert Motzer, Dana Tsui, Martin Voss Memorial Sloan Kettering Cancer Center presents…
Bryan Lewis, President KidneyCan discusses An Advocates Perspective to Increasing Funding Resources at the 18th International Kidney Cancer Symposium 2019,…
Christopher Wood, MD from MDAnderson holds a kidney cancer tumor board with real cases from the Kidney Cancer Association annual…
Hans Hammers MD, PhD presents Radiation to Prime the Immune System Filmed at the 18th International Kidney Cancer Symposium 2019,…
Robert Hapke, Katherine E. Beckermann MD/PhD, W. Kimryn Rathmell MD/PhD, and Scott M. Haake MD Vanderbilt-Ingram Cancer Center Vanderbilt University…
Abhishek Tripathi MD Assistant Professor, Section of Hematology Oncology University of Oklahoma Stephenson Cancer Center Oklahoma City, OK presents Immune…
Leigh Ellis Department of Oncologic Pathology Dana-Farber Cancer Institute Harvard Medical School presents Using Epigenetic Therapy to Enhance Immunotherapy Response…
Thai Ho Mayo Clinic Arizona presents Therapeutic targeting of the extracellular matrix in kidney cancer Filmed at the 18th International…
Charles G. Drake MD / PhD Director GU Medical Oncology Co-Director: Immunotherapy Program Associate Director for Clinical Research Professor of…
Aguirre A. de Cubas, Ph.D. Post-Doctoral Fellow WK Rathmell Lab Vanderbilt University Medical School presents DNA Demethylation promotes ERV expression…
Haydn Kissick, Ph.D. Department of UrologyDepartment of Microbiology and Immunology presents The T-cell response to Kidney Cancer Filmed at the…
Arlene Sharpe M.D. Ph.D. Department of Immunology Harvard Medical School presents Discovery of new IO Targets Leveraging CRISPR Filmed at…
Patient-reported ECOG performance status (PS) is lower than oncologist-reported PS and is associated with worse psychosocial outcomes. Cristiane Decat Bergerot,…
Meredith M. Regan,1 Michael B. Atkins,2 Thomas Powles,3 Lillian Werner,4 Charlene Mantia,5 Shuo Yang,6 Jennifer L. Johansen,6 Sumati Rao,6 Kyna…
Chung-Han Lee1, Amishi Y. Shah2, Vicky Makker1, Matthew Taylor3, David Shaffer4, James J. Hsieh5, Allen L. Cohn6, Chris DiSimone7, Alvaro…
Steven P. Rowe, MD, PhD Division of Nuclear Medicine and Molecular Imaging Russell H. Morgan Department of Radiology and Radiological…
I. Alex Bowman, MD Assistant Professor, Division of Hematology/Oncology UT Southwestern Medical Center, Dallas, TX Co-Authors: Marianna Dakanali, Guiyang Hao,…
Haris Zahoor, Akash Sali, Manju Aron, Imran Siddiqui, Bino Varghese, Steven Cen, Xiaomeng Lei, Anishka D’Souza, Austin Fullenkamp, Mihir Desai,…
Zhen J. Wang, MD Professor of Radiology Department of Radiology and Biomedical Imaging University of California, San Francisco discusses Hyperpolarized…
Ivan Pedrosa, MD PhD Professor of Radiology, Urology, Advanced Imaging Research Center and Biomedical Engineering University of Texas Southwestern, Dallas,…
Allan Pantuck, MD, MS, FACS Professor and Vice Chair, Urology Institute of Urologic Oncology David Geffen School of Medicine at…
Martin H. Voss1, Arun Azad2, Aaron R. Hansen3, Jhanelle E. Gray4, Sarah J. Welsh5, Xuyang Song6, Ikbel Achour6, Heping Hu6,…
Ritesh Kotecha1, Ronan Flippot2, Sujata Patil1, Taylor Nortman1, Annalisa Guida2, Ashley Foster1, Bernard Escudier2, Robert Motzer1, Laurence Albiges2, Martin Voss1…
Viraj Master MD PhD FACS Professor Fray F. Marshall Chair in Urological Research Department of Urology Director of Integrative Oncology…
Elad Sharon, MD, MPH Senior Investigator/Medical Officer Cancer Therapy Evaluation Program Division of Cancer Therapy & Diagnosis National Cancer Institute…
Tian Zhang, MD, MHS discusses Aiming to personalize immunotherapy with existing and emerging biomarkers at the 18th International Kidney Cancer…
André P. Fay, MD, PhD Professor, PUCRS School of Medicine Chief, Medical Oncology Department – OncoclÃnicas/HSL-PUCRS Visiting Scientist at Dana-Farber…
Walter Stadler, MD FACP Dean for Clinical Research Deputy Director Comprehensive Cancer Center University of Chicago discusses Favorable Risk Renal…
Michael R. Harrison, MD Associate Professor of Medicine Duke Cancer Institute discusses Active Surveillance for Favorable Risk mRCC at the…
Deborah Maskens MA MSM International Kidney Cancer Coalition discusses Unmet Patient Needs: Results from IKCC Global Survey at the 18th…
David Braun, MD, PhD DF/HCC Kidney Cancer SPORE Harvard Medical School discusses Understanding CD8+ T Cell Function and Specificity in…
Toni K. Choueiri, MD On Behalf of DF/HCC SPORE leadership PI: McDermott and Kaelin gives an overview of the Dana-Farber/Harvard…
Srinivas Malladi, Ph.D. Harold C. Simmons Comprehensive Cancer Center, Department of Pathology University of Texas Southwestern Medical Center, Dallas, TX…
James Brugarolas, M.D., Ph.D. Director, Kidney Cancer Program Principal Investigator, Kidney Cancer SPORE Sherry Wigley Crow Endowed Chair in Cancer…
Mark H. Michalski MD Executive Director, Center for Clinical Data Science Massachusetts General Hospital/Brigham and Women’s Hospital discusses How Artificial…
W. Kimryn Rathmell, MD, PhD Professor of Medicine and Biochemistry; Director, Division of Hematology and Oncology Vanderbilt University Medical Center…
Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Changing Paradigms…
Javid J. Moslehi, M.D. Associate Professor of Medicine Director, Cardio-Oncology Program Co-Director, Vanderbilt Program for Optimizing Immuno-oNcology Therapy (V-POINT) Vanderbilt…
Bianca D. Santomasso MD, PhD Assistant Professor, Department of Neurology Memorial Sloan Kettering Cancer Center discusses Current Management Strategies for…
Yinghong (Mimi) Wang, MD, PhD Director of Medication-Induced Colitis and Enteritis Director of Fecal Microbiota Transplantation Department of Gastroenterology, Hepatology…
Raja-Elie E. Abdulnour, M.D. Assistant Professor of Medicine Pulmonary and Critical Care Medicine DFCI / BWH discusses Current Management Strategies…
Kerry Reynolds, MD Clinical Director, Inpatient Oncology UnitsDirector, Severe Immunotherapy Complications ServiceMassachusetts General Hospital, Boston, MA discusses Establishing an Immune…
Gopal N. Gupta, MD, FACS Associate Professor Departments of Urology, Surgery and Radiology Fellowship Director, Society of Urologic Oncology Cardinal…
Raj Ayyagari M.D. Assistant Professor of Radiology Department of Radiology Yale University School of Medicine discusses What is Optimal for…
Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology MD Anderson discusses the Optimal Management…
Rod J Ellis, M.D. FACRO Professor and Chair Radiation Oncology Penn State University Milton Hershey Medical Center Hershey Pennsylvania discusses…
Stenio de Cássio Zequi, MD, MSc, PhD Head of Referral Center for Urological Tumors Robotic and HIFU Programs at AC…
Alexander Kutikov, MD, FACS Professor and Chief, Urologic Oncology Fox Chase Cancer Center, Philadelphia, PA discusses Treatment of the Cystic…
William C Huang, MD Associate Professor and Vice Chair of Urology NYU School of Medicine Chief of Urology and Co-Director…
Steven C. Campbell, MD, PhD Professor Surgery, Vice Chair, Program Director Section of Urologic Oncology, Department of Urology Glickman Urological…
Sasan Setoodeh, MD Genitourinary Pathology Fellow University of Texas Southwestern, Dallas, Texas discusses the Effects of Immune Checkpoint Inhibitors on…
Neil Mendhiratta MD, MS UCLA David Geffen School of Medicine discusses the Identification of Oncocytic Neoplasms with Cyclin D1 Immunohistochemistry…
Gennady Bratslavsky, M.D. Professor and Chairman Department of Urology Upstate Medical University Syracuse, NY discusses Surgical Insights For Variant Histology…
Matt Campbell MD Assistant Professor GU Medical Oncology discusses The Argument for Front Line TKI based treatment for non-clear cell…
Primo N. Lara, Jr., MD Director, UC Davis Comprehensive Cancer Center Professor of Medicine and Executive Associate Dean UC Davis…
Eric C. Kauffman, MD Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo NY Kidney Cancer Association Meeting, Miami FL…
Nizar M. Tannir, MD, FACP Ransom Horne, Jr. Professor for Cancer Research Professor and Chair ad interim Department of Genitourinary…
Ying-Bei Chen, MD, PhD Associate Attending Pathologist Memorial Sloan Kettering Cancer Center discusses the Importance of Tumor Profiling for Rare…
Michelle Hirsch, MD, PhD Associate Professor of Pathology Chief, Genitourinary Pathology Service Brigham and Women’s Hospital Harvard Medical School discusses…
EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with BAVENCIO in combination with…
Emily Bernstein, PhD of @IcahnMountSinai answers neuroblastoma in older children: what happens when you have an ATRX deletion?
Emily Bernstein, PhD of @IcahnMountSinai explains neuroblastoma in older children & adolescents harboring deletions within a gene called ATRX may…
Chung-Han Lee, MD @ChungHanLee3 of @sloan_kettering answers how it affects clinicians and what is to come in kidney cancer. _______…
Chung-Han Lee, MD @ChungHanLee3 of @sloan_kettering explains questions asked by his colleagues: was the improvement in progression-free survival clinically meaningful?…
Chung-Han Lee, MD @ChungHanLee3 of @sloan_kettering discusses data from randomized #ENTRATA Study in patients with advanced RCC. __________ Data shared…
COG study shows treatment can be reduced without compromising outcomes Study shows therapy can be reduced in some neuroblastoma patients…
September 28, 2019 Â Data shared today in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival…
– Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved…
Sarmad Sadeghi, MD of USC Norris Comprehensive Cancer Center explains the role of nephrectomy is getting smaller and smaller in…
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains how the landscape is changing in treating metastatic…
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the anticipated trial results involving I-O, TKIs and…
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, discusses strategies for the 2nd line renal cell carcinoma…
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, provides perspective on treating newly diagnosed renal cell carcinoma…
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the studies and outcomes in sarcomatoid renal cell…
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the design on the outcomes of the PDIGREE…
Ziad Bakouny MD @ZiadBakouny Of Dana-Farber Cancer Institute Discusses Updates On Sarcomatoid & Rhabdoid Renal Cell Carcinoma: Immune Checkpoint Inhibitors…
Toni Choureiri, MD, discusses the biomarker analyses from JAVELIN Renal 101. Background: The phase 3 JAVELIN Renal 101 trial in…
Elizabeth R. Plimack MD MS @ERPlimackMD Of The Fox Chase Cancer Center Discusses Metastatic RCC Metastasectomy Study: Procedure Does Not…
Daniel George MD @daniel_j_george Of Duke University Cancer Institute Discusses S-TRAC Study Data: Took 3 Years To Complete, Disease Free…
Daniel George MD @daniel_j_george Of Duke University Cancer Institute Discusses Adjuvant Therapy In RCC: Very Controversial But Needs Continual Development,…
Elizabeth R. Plimack MD MS @ERPlimackMD Of Fox Chase Cancer Center Discusses CARMENA Study: Looking At Cytoreductive Nephrectomy In Metastatic…
Elizabeth R. Plimack MD MS @ERPlimackMD Of Fox Chase Cancer Center Discusses KEYNOTE-426: Pembrolizumab Plus Axitinib VS Sunitinib For Advanced…
Toni Choueiri M.D. Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute/Brigham and Womens Hospital and…
Toni Choueiri M.D. Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute/Brigham and Womens Hospital and…
Toni Choueiri M.D. Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute/Brigham and Womens Hospital and…
David Quinn M.D., PhD Associate Professor of Medicine (Clinical Scholar);Section Head, Genitourinary (GU) Oncology, Division of Cancer Medicine and Blood…
David Quinn M.D., PhD Associate Professor of Medicine (Clinical Scholar);Section Head, Genitourinary (GU) Oncology, Division of Cancer Medicine and Blood…
Jose Karam M.D., FACS Associate Professor in the Department of Urology at The University of Texas MD Anderson Cancer Center…
Laurence Albiges M.D., PhD medical oncologist in the Genitourinary group of the Department of Cancer Medicine at the Institute Gustave…
Laurence Albiges M.D., PhD medical oncologist in the Genitourinary group of the Department of Cancer Medicine at the Institute Gustave…
Axel Bex M.D. Department of Urology The Netherlands Cancer Institute Amsterdam Discusses Surgical Consequences Of Pretreating Patients With RCC. At…
Axel Bex M.D. Department of Urology The Netherlands Cancer Institute Amsterdam Discusses Surgery Or Therapy First. At The Fourteenth European…
Axel Bex M.D. Department of Urology The Netherlands Cancer Institute Amsterdam Discusses Elaborating On The CARMENA Trial. At The Fourteenth…
Axel Bex M.D. Department of Urology The Netherlands Cancer Institute Amsterdam Discusses Perioperative Therapy In The CARMENA & PROBE Trials.…
Grant Stewart PhD an academic surgeon at the University of Cambridge Discusses Why One Year Of Treatment With Dosing Of…
Grant Stewart PhD an academic surgeon at the University of Cambridge Discusses Elaborating On Multiple Kidney Cancer Studies. At The…
Grant Stewart PhD an academic surgeon at the University of Cambridge Discusses Two IO Plus TKI Studies In Kidney Cancer.…
Alessandro Volpe M.D. of the University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy Discusses Treating Renal Masses…
Alessandro Volpe M.D. of the University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy Discusses Criteria To Indicate…
Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses…
Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses…
Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses…
Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses…
Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses…
Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses…
Daniel Goldstein MD Tel Aviv University discusses Moving from Observational Pharmacoeconomics to Interventional Pharmacoeconomics at the Kidney Cancer Association International…
Cristina Suárez MD PhD Hospital Universitari Vall d´Hebron-Vall d´Hebron Institute of Oncology discusses SPAIN: SOGUG MODEL at the Kidney Cancer…
Tim OBrien Vice President of BAUS discusses Centralization of Nephrectomy in the UK The good the bad and the ugly…
Toni K. Choueiri, MD Director, The Lank Center for Genitourinary Oncology Dana-Farber Cancer Institute discusses The Combination of Avelumab +…
Ronan FlippotMD MSc discusses Brain Metastases in Renal Cell CarcinomaAre immune checkpoint inhibitors up to the task? discusses Brain Metastases…
Raquel Perez-Lopez Vall dHebron Institute of Oncology (VHIO)Principal Investigator-Radiomics Group discusses Recist vs iRecist: Clinically Significant? at the Kidney Cancer…
Frede Donskov, M.D., DMSc Professor of Oncology Chairman, Kidney Cancer Expert Committee, Danish Medicines Council Aarhus University Hospital Denmark discusses…
Brian i. Rini, MD Cleveland Clinic discusses Axi/Pembro is the Standard of Care in mRCC at the Kidney Cancer Association…
Samra Turajlic The Royal Marsden NHS Foundation Trust, London, UK discusses the second part of A phase II study of…
Dr Pablo Maroto Hospital Sant Pau Barcelona discusses New Network Around Oncologists at the Kidney Cancer Association International Symposium 2019…
Jean-Marie Michot, MD Drug Development Department Gustave Roussy, France jean-marie.michot@gustaveroussy.fr discusses IO toxicities in Kidney Cancer at the Kidney Cancer…
Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology discusses  Update in IO Neoadjuvant (Preoperative)…
Cristina Suárez MD PhD Hospital Universitari Vall d´Hebron-Vall d´Hebron Institute of Oncology discusses NEW TARGETS IN RCC:NKTR at the Kidney…
Brian Shuch, MD Associate Professor of Urology Director, UCLA Kidney Cancer Program Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer…
Monika Wolkers, PhD m.wolkers@sanquin.nl discusses TIL products from Renal Cell Carcinomas are tumor-specific but poor cytokine producers at the Kidney…
Bernadett Szabados of Barts Cancer Institute discusses NEW TARGETS IN RCC at the Kidney Cancer Association International Symposium 2019 in…
W. Kimryn Rathmell, MD, PhD of Vanderbilt Ingram Cancer Center discusses Novel epigenetic targeting approaches at the Kidney Cancer Association…
Toni K. Choueiri MD of Dana Farber discusses Randomised phase 2 study of sapanisertib (TAK?228/MLN0128) ± TAK-117 versus everolimus in…
Philip Zeuschner, MD of Universität des Saarlandes, Saarbrücken (UKS) discusses Learning curves in 500 robot-assisted partial nephrectomies: the bed-side assistant…
Prof. Alessandro VOLPE University of Eastern Piedmont Maggiore della Carità Hospital, Novara, Italy discusses SMALL RENAL MASSES NON SURGICAL MANAGEMENT…
Manuela Schmidinger, MD, Camillo Porta, MD, Romano Danesi, MD, PhD, Brian I. Rini, MD discuss Optimising advanced RCC treatment: the…
Dr Emmanuel MEYER Department of radiation oncology Centre François Baclesse Caen – France discusses Oligometastatic disease: Localized vs systemic therapy…
Fernando Gómez Muñoz. MD PhD Vascular and Interventional Radiology Hospital Clinic de Barcelona Hospital Sant Joan de Deu, Barcelona Netherlands…
Stereotactic Ablative Body RadioTherapy in Kidney Cancer Ben Vanneste, MD, PhD Radiation-Oncologist, MAASTRO Clinic, The Netherlands discusses Stereotactic Ablative Body…
Dr Kevin Litchfield Kevin.litchfield@crick.ac.uk Twitter: @kevlitchfield discusses Genomic and Transcriptomic Biomarkers of IO Response in RCC at the Kidney Cancer…
Grant D Stewart, MD Surgical Oncology Lead, University Lecturer, University of Cambridge Consultant Urological Surgeon, Addenbrookes Hospital discusses Adjuvant immuno-oncology…
James Larkin of the The Royal Marsden NHS Foundation Trust pays tribute to his friend and legendary oncologist Martin Gore…
Thomas Powles Director of Barts Cancer Center. Professor of Urology Cancer, Barts Cancer Institute discusses firist line clear cell RCC:…
W. Kimryn Rathmell, MD, PhD Director of the Division of Hematology and Oncology Vanderbilt University Medical Center discusses Endogenous retrovirus…
Samra Turajlic, MD The Royal Marsden NHS Foundation Trust outlines Cell-free tumour DNA (cfDNA) detection in advanced renal cell carcinoma…
Christopher Wood, MD MD Anderson Cancer Center expresses his thoughts on the late Martin Gore at the Kidney Cancer Association…
David Quinn, MD USC Norris Comprehensive Cancer Center gives a heartfelt tribute to Dr. Martin Gore and his US/International Perspective…
Bernard Escudier of the Institut Gustave Roussy in Villejuif, France reminisces about his late friend Martin Gore at the Kidney…
Tobias Klatte, MD, PhD, FEBU, FRCS(Ed) Consultant Urological Surgeon, Royal Bournemouth Hospital Visiting Researcher, University of Cambridge Honorary Lecturer, University…
This presentation aims to provide an overview of the mRCC patient journey and the challenges clinicians face. To explore how…
Andy Thomas from Kidney Cancer Support Network discusses Cytoreductive Nephrectomy Patient Perspective at the Kidney Cancer Association International Symposium in…
Axel Bex Royal Free London NHS Foundation Trust, UCL Division of Surgical and Interventional Science, London, UK and The Netherlands…
Michael Staehler, M.D. Ph.D. Head Interdisciplinary Center on Renal Tumors Department of Urology University of Munich, Germany takes the PROCytoreductive…
Lorenzo Marconi, MD, FEBU Coimbra, Portugal discusses Clinical Marker for Cytoreductive Nephrectomy? at the Kidney Cancer International Symposium in Dubrovnik…
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses Discussing PEDIGREE Study. At The 2019 Genitourinary Cancers Symposium…
Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses Recent Data Examining Atezolizumab And…
Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses The Implications Of CHECKMATE 214…
Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses Outcomes Of The KEYNOTE 426…
Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses TIVO-3 Study In Highly Refractory…
Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses How To Differentiate Between TKIs…
Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses Next Steps When Treating mRCC…
Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical…
Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical…
Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical…
Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical…
Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical…
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses The Outcomes Of KEYNOTE 426 Presented At GU 2019.…
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses Intermediate/Poor And Favorable Risk RCC Patients. At The 2019…
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses Predictive Biomarkers In Selecting Patient Populations For I-O Treatment…
John Leppert, M.D., M.S. Associate Professor – Med Center Line, Urology At Stanford University Discusses Which Patient For Which Treatment.…
John Leppert, M.D., M.S. Associate Professor – Med Center Line, Urology At Stanford University Discusses Over-Diagnosis & Over-Treatment Of Kidney…
John Leppert, M.D., M.S. Associate Professor – Med Center Line, Urology At Stanford University Discusses Increasing Awareness In Kidney Cancer.…
John Leppert, M.D., M.S. Associate Professor – Med Center Line, Urology At Stanford University Discusses How To Better Treat Kidney…
Abhishek Tripathi, M.D. Assistant Professor Of Medicine In The Section Of Hematology/Oncology At Oklahoma Stephenson Cancer Center Discusses Adenosine Pathway…
Tian Zhang, M.D. Medical Oncologist at Duke University specializing in caring for patients with genitourinary cancers, including kidney, bladder, prostate,…
Tian Zhang, M.D. Medical Oncologist at Duke University specializing in caring for patients with genitourinary cancers, including kidney, bladder, prostate,…
Tian Zhang, M.D. Medical Oncologist at Duke University specializing in caring for patients with genitourinary cancers, including kidney, bladder, prostate,…
Tian Zhang, M.D. Medical Oncologist at Duke University specializing in caring for patients with genitourinary cancers, including kidney, bladder, prostate,…
Tian Zhang, M.D. Medical Oncologist at Duke University specializing in caring for patients with genitourinary cancers, including kidney, bladder, prostate,…
Samra Turajlic, M.D. Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, Discusses What To Achieve With The TRACERx…
Samra Turajlic, M.D. Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, Discusses Results From TRACERx Renal Study. At…
Samra Turajlic, M.D. Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, Discusses The TRACERx Renal Study. At the…
Brian Shuch, M.D. Associate Professor of Urology at UCLA Discusses, Tumor Enucleation Debate. At the Seventeenth International Kidney Cancer Symposium…
Brian Shuch, M.D. Associate Professor of Urology at UCLA Discusses, Overview of Sessions From KCA Miami. At the Seventeenth International…
Brian Shuch, M.D. Associate Professor of Urology at UCLA Discusses, Tumor Enucleation. At the Seventeenth International Kidney Cancer Symposium on…
Brian Shuch, M.D. Associate Professor of Urology at UCLA Discusses, Benefits Of Tumor Enucleation. At the Seventeenth International Kidney Cancer…
Sumantra Kumar Pal, M.D. Assistant professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Kidney…
Sumantra Kumar Pal, M.D. Assistant professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Kidney…
Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Upcoming Data Coming In 2019. At the Seventeenth International Kidney…
Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Profiling Tumor Microenvironment. At the Seventeenth International Kidney Cancer Symposium…
Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Next Gen Immune Activation In Kidney Cancer. At the Seventeenth…
Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Figuring Out Best Drug Combo For Kidney Cancer. At the…
Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Discussing Combining Drugs In Kidney Cancer. At the Seventeenth International…
Alexander Kutikov, M.D. Chief, Division of Urology and Urologic Oncology Professor At Fox Chase Cancer Center, Department of Surgical Oncology…
Alexander Kutikov, M.D. Chief, Division of Urology and Urologic Oncology Professor At Fox Chase Cancer Center, Department of Surgical Oncology…
Steven Chang, M.D., M.S. Urologic Oncologist and Health Service Researcher at Brigham and Women’s Hospital discusses Should We Be Doing…
David Braun, M.D., Phd an Oncologist at Dana-Farber Cancer Institute in Boston MA. discusses Why Not Use Bulk RNA Sequencing…
David Braun, M.D., Phd an Oncologist at Dana-Farber Cancer Institute in Boston MA. discusses The Future Of Single Cell RNA…
David Braun, M.D., Phd an Oncologist at Dana-Farber Cancer Institute in Boston MA. discusses Single Cell RNA Sequencing In Kidney…
David Braun, M.D., Phd an Oncologist at Dana-Farber Cancer Institute in Boston MA. discusses Next Step In Single Cell RNA…
David Braun, M.D., Phd an Oncologist at Dana-Farber Cancer Institute in Boston MA. discusses Next Step In Single Cell RNA…
David Braun, M.D., Phd an Oncologist at Dana-Farber Cancer Institute in Boston MA. discusses How To Deal With Intra &…
CRISTIANE DECAT BERGEROT, PhD PSYCHOLOGIST, POSTDOCTORAL FELLOW CITY OF HOPE COMPREHENSIVE CANCER CENTER discusses THE IMPACT OF THE PSYCHOSOCIAL MILIEU…